Study of CMTS1215 Injection in Patients With Solid Tumors

This is a prospective, open-label, single-arm exploratory clinical trial to evaluate the safety and efficacy of CMTS1215 (Proteus mirabilis) oncolytic bacteria injection for the treatment of solid tumors. The study aims to enroll at least 8 patients with histologically confirmed solid tumors who have failed or are unable to complete conventional first-line, second-line, or third-line anti-tumor therapies.

NCT Number	NCT07556276
Lead Sponsor	The Second Hospital of Nanjing Medical University
Conditions	Solid Tumor
Enrollment	20 participants
Start Date	2025-03-06
Primary Completion	2030-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-29